Mairs & Power Inc’s United Therapeutics UTHR Stock Holding History

Mairs & Power Inc’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-350	Closed	-$208K	–	262
2026 Q1	$208K	Buy	+350	New	+$174K	﹤0.01%	238

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Mairs & Power Inc's UTHR Position: Q2 2026 in Review

Mairs & Power Inc sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 350 shares — an estimated $208K sold.

Mairs & Power Inc first reported a position in UTHR in Q1 2026 and held it in 1 quarter. The position peaked at $208K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Mairs & Power Inc reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Mairs & Power Inc sold 350 United Therapeutics shares in Q2 2026, an estimated $208K.
Mairs & Power Inc first reported a position in United Therapeutics in Q1 2026 and held it in 1 quarter.
Mairs & Power Inc's United Therapeutics position peaked at $208K in Q1 2026.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Mairs & Power Inc's 13F filing for Q2 2026, filed 14 Aug 2026.